Tristel launches FDA-cleared ophthalmic disinfectant at US conference

Tristel plc (AIM:TSTL) unveiled its newly FDA-cleared Tristel OPH, a high-level disinfectant for ophthalmic instruments, at the APIC 2025 conference, drawing significant interest from U.S. health systems. This launch, alongside its Tristel ULT disinfectant and digital traceability platform, reinforces Tristel's expanding footprint in the U.S. medical device disinfection market, with Tristel OPH stock expected to be available in August 2025.

Analysis

Tristel plc (TSTL) has achieved a significant regulatory and commercial milestone with the U.S. Food and Drug Administration (FDA) clearance and subsequent launch of its Tristel OPH disinfectant at the APIC 2025 conference. This entry into the U.S. ophthalmology market, a key healthcare segment, is bolstered by reports of "significant interest" and direct engagement from U.S. health systems, signaling strong potential for market adoption. The launch is a critical component of the company's broader U.S. expansion strategy, complementing its existing FDA-cleared Tristel ULT disinfectant and its digital traceability platform, Tristel 3T. The stated commercial availability of Tristel OPH in August 2025 provides a clear timeline for investors to anticipate the commencement of a new revenue stream. The current phase of supporting clinical trials and internal validations is a crucial step in converting initial interest into tangible sales contracts, effectively de-risking future commercialization efforts.

Key Decisions for Investors

• Given the FDA clearance and positive initial market feedback, investors should consider the successful launch of Tristel OPH a key potential catalyst for revenue growth beginning in the second half of 2025.
• It is critical to monitor company communications regarding the progress of pre-launch institutional trials and validations, as the conversion of initial interest into firm adoption will be the primary driver of the product's commercial success.
• The performance of Tristel OPH in the U.S. can be viewed as a barometer for the company's broader ability to execute its expansion strategy and commercialize its entire suite of infection prevention products in the lucrative American market.